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Simple Summary: Glioblastoma (GB) is the deadliest type of primary brain tumor. Following diag-
nosis the patient´s median survival is only 16 months. There are currently around 450 clinical trials
focused on the development of more effective therapies for GB. Nevertheless, radiotherapy remains
the most clinically relevant and effective treatment for this devastating disease. Unfortunately, radio-
therapy resistance (radioresistance) is frequently observed in GB patients. As a consequence tumor
regrowth (recurrence) occurs and eventually the patient succumbs to the disease. It is crucial to fully
understand the mechanisms by which GB cells become resistant to radiation in order to improve the
sensitivity of these cells to radiotherapy and develop novel strategies to overcome this issue. In this
review, we examined how low tumor oxygenation (known as hypoxia) which is a main feature of GB
contributes to radioresistance to better understand the implications of this tumor microenvironment
in GB treatment and recurrence.
Abstract: Glioblastoma (GB) (grade IV astrocytoma) is the most malignant type of primary brain
tumor with a 16 months median survival time following diagnosis. Despite increasing attention
regarding the development of targeted therapies for GB that resulted in around 450 clinical trials
currently undergoing, radiotherapy still remains the most clinically effective treatment for these
patients. Nevertheless, radiotherapy resistance (radioresistance) is commonly observed in GB patients
leading to tumor recurrence and eventually patient death. It is therefore essential to unravel the
molecular mechanisms underpinning GB cell radioresistance in order to develop novel strategies and
combinational therapies focused on enhancing tumor cell sensitivity to radiotherapy. In this review,
we present a comprehensive examination of the current literature regarding the role of hypoxia (O2
partial pressure less than 10 mmHg), a main GB microenvironmental factor, in radioresistance with
the ultimate goal of identifying potential molecular markers and therapeutic targets to overcome this
issue in the future.
Keywords: glioblastoma (GB); hypoxia; radiotherapy; Hypoxia Inducible Factor (HIF); radioresis-
tance; glioma stem cells (GSC)
1. Introduction
Glioblastoma (GB) is classified by the World Health Organization (WHO) as a grade
IV astrocytoma. It is the deadliest primary malignant brain tumor; the median patient
survival time being only 16 months [1–3].
The current classification of the Central Nervous System (CNS) tumors by the WHO
combines both their histopathological name followed by the characteristic genetic signa-
ture [4]. In accordance to this, GB is classified as GB, IDH-wildtype which is the most
prevalent type, corresponding to approximately 90% of all cases, and GB, IDH-mutant.
Over 90% of GB develop de novo, called primary GB. However, a minority of GB develop
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slowly from low-grade astrocytomas (secondary GB). Mutations in IDH are more frequently
observed in secondary GB. There are three Isocitrate Dehydrogenase (IDH) enzymes (IDH1,
IDH2 and IDH3), but only IDH1 and IDH2 enzymes have been shown to be mutated in GB.
IDHs are responsible for the conversion of isocitrate to α-ketoglutarate. This process results
in the production of the reducing agent Nicotinamide Adenine Dinucleotide Phosphate
(NADPH). IDH-mutant enzymes have approximately 50% less activity compared to IDH
wild-type (WT) proteins. This results in impaired production of bioenergy (NADPH) and
intermediates and the production of the onco-metabolite 2-hydroxyglutarate (2-HG) which
causes epigenetic changes. 2-HG via hyper-methylation leads to the loss of differentiation
of GB cells. These changes caused by IDH mutation lead to reduced GB, IDH-mutant
tumor growth compared to GB, IDH-WT. This consequently translates to a better overall
prognosis for patients with GB, IDH-mutant [5].
GB has been further sub-classified into classical, proneural, neural and mesenchymal
sub-types based on specific genetic signatures [6,7]. In this way, the classical sub-type is
characterized by Epidermal Growth Factor Receptor (EGFR) gene amplification or mutation
(leading to a constitutively active receptor) as well as by over-expression of neural stem
cell genes. These include Sonic hedgehog, Notch and NES [7]. The proneural sub-type shows
a gene signature characterized by over-expression of many proneural genes (e.g., DCX,
SOX, TCF4, ASCL1 and DLL3), amplification of the Platelet-Derived Growth Factor Receptor
A (PDGFRA) gene and inactivation or loss of TP53 [7,8]. In addition, IDH mutations are
more common within the proneural subtype [9]. The expression of neuron gene markers,
such as NEFL, GABRA1, SYT1 and SLC12A5 is a hallmark of the neural sub-type [7]. Lastly,
the mesenchymal sub-type signature includes the expression of mesenchymal genes (e.g.,
CHI3L1 and MET) [8] as well as inactivating mutations or deletion of the Neurofibromin 1
(NF1) gene [7,10,11].
The current standard treatment for GB was established in 2005 by Roger Stupp and
colleagues [12]. The so called “Stupp protocol” encompasses GB resection surgery (when
possible as evaluated by MRI imaging) after what concurrent radiotherapy and chemother-
apy with temozolomide (TMZ) are implemented. This is followed by additional 6 cycles of
TMZ administration [12]. Radiotherapy alone can considerably increase patient survival.
However, beneficial effects of chemotherapy with TMZ are most commonly observed in a
sub-set of patients whose tumors contain O6-methylguanine DNA methyltransferase (MGMT)
promoter methylation [1,9]. MGMT promoter methylation is also a prognostic factor associ-
ated with longer survival irrespective of TMZ treatment as well as longer post-progression
survival (3–4 months) in patients with recurrent GB [13]. MGMT is a DNA repair enzyme
that fixes damaged guanine nucleotides (O6-methylguanine) via transferring the methyl
group at the O6 site of guanine to its cysteine residues. This reverts the gene mutation and
subsequently avoids cell death induced by alkylating agents such as TMZ [14]. Several
studies have demonstrated that regulation of MGMT expression in GB occurs mainly via
epigenetic modification, namely through the methylation of CpG islands within the MGMT
promoter. This leads to heterochromatinization which is accompanied by rearrangement
and random localization of nucleosomes. Consequently, binding of transcription factors to
the MGMT promoter becomes impaired [14].
The current standard radiotherapy dosage is a total of 60 Grays (Gy) in fractions of
2 Gy, administered 5 days a week for 6 weeks [12]. TMZ is concurrently administrated at a
dose of 75 mg/m2 daily for 6 weeks. After a rest period of one month, TMZ chemotherapy
is restarted at a dose of 150 mg/m2 daily for 5 days in the first month cycle. If this dose is
tolerated, it can be increased up to 200 mg/m2 for 5 days per month. TMZ is administrated
for 6 months after radiotherapy, but many physicians continue TMZ administration for
12–18 months even though it has not been proved to increase overall survival [12,15].
Worryingly, almost all GB patients develop resistance to current therapy and eventually
succumb to the disease.
Despite the development of a large number of studies and hundreds of ongoing
clinical trials, GB treatment has not changed since 2005 [9,12]. Understanding the complex
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biology of GB and the role of the tumor microenvironment is therefore crucial to develop
novel and effective treatments in GB.
GB pathological features include hypoxic foci (where O2 partial pressure is less than
10 mmHg) containing necrotic cores. The hypoxic areas are surrounded by cell pseudopal-
isades and microvascular hyperplasia [9]. Research suggests that cellular pseudopalisades
constitute invasive fronts of the tumor that likely originated from GB cells migrating away
from the hypoxic regions. These cells over-secrete proangiogenic factors leading to an
intensified form of angiogenesis which is known as microvascular hyperplasia [9].
The GB hypoxic microenvironment has been shown to be highly associated with
tumor invasion and resistance to chemo- and radiotherapy which are the main causes of
death in GB patients [16,17]. Importantly, dynamic contrast enhanced MRI analyses have
indicated that Hypoxia Inducible Factor 1 (HIF-1) (hypoxia marker) and Vascular Endothe-
lial Growth Factor A (VEGFA) staining and tumor vascularity significantly correlate with
worse progression-free and overall GB patient survival [18,19].
In this review article, we examined the existing literature regarding the role of hy-
poxia in supporting radiotherapy resistance in GB with the aim to better understand the
implications of this tumor microenvironment in GB treatment and recurrence.
2. Basic Principles of Cancer Radiotherapy
Radiotherapy is currently the major and most effective treatment modality for GB
patients. Nevertheless, radioresistance remains a major clinical problem for these patients.
Ionizing radiation (IR) was discovered just before the turn of the 20th century by
Marie and Pierre Curie and Wilhelm Conrad Roentgen [20]. It was during the 1920s that
cancer radiotherapy was piloted and significantly evolved [20] due to several technologic
and research advances. These included the invention by Coolidge et al. of a sealed-off
vacuum x-ray tube which could be operated at 180,000 to 200,000 volts which introduced
the kilovoltage era in radiotherapy. Another important advancement that contributed to
the effectiveness of radiotherapy at that time was the development of the first quantitative
methods for the measurement of radiation dose and of the first physical unit of dose, the
roentgen (later replaced by the rad). Lastly, the experimental and clinical radiobiology re-
search work led by Claude Regaud at the Fondation Curie in Paris pioneered the procedure
and development of fractionated radiotherapy which is still currently in use [20].
The ability of IR to kill tumor cells relies mainly on its DNA damaging effects. This
damage can occur either directly on the DNA molecules (accounting for 30–40% of lesions),
or indirectly through the generation of free radicals such as reactive oxygen species (ROS)
or reactive nitrogen species (RNS) that in turn damage the DNA molecules (responsible for
60–70% of lesions) [21,22].
Water radiolysis is a main process in the formation of free radicals (ROS) by IR,
resulting in the formation of electrons, H˙ atoms, OH˙ radicals, H3O+, OH− ions and
dihydrogen (H2) and hydrogen peroxide (H2O2) molecules [23].
IR produces a spectrum of DNA base lesions, the most prevalent being 8-oxo-guanaine
(8-oxoG), thymine glycol (5,6-dihydroxy-5,6-dihydrothymine) and formamidopyrimidines [4,6-
diamino-5-formamidopyrimidine (FapyAde) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine
(FapyGua)] [24]. In addition, IR produces DNA Single Strand Breaks (SSBs) that have
a unique signature, generating 3′ phosphate or 3′-phosphoglycolate ends rather than
3′-OH ends. Particularly important IR induced lesions are double strand breaks (DSBs)
which occur due to multiple damaged sites closely located on both strands of the DNA
molecule [24]. DSBs are more difficult to repair compared to SSBs leading to cancer cell
death [25]. DSBs typically trigger DNA-damage responses (DDR). However, when DSBs
cannot be efficiently repaired by the cellular DDR mechanisms, irradiated cells undergo the
so-called mitotic catastrophe which is a major cell death mechanism caused by IR-induced
DNA damage [26].
Typically, a dose of 1Gy of X-ray radiation produces around 3000 damaged bases,
1000 SSBs and 40 DSBs [22].
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The decreased oxygen levels observed in hypoxic GB cells, lead to resistance to IR due
to the reduced availability of oxygen which is needed to stabilize the DNA strand breaks
caused by radiotherapy [27]. Under normoxic conditions (physiological or normal oxygen
levels, where tissue oxygenation is around 40 mmHg), cells are vulnerable to IR due to
oxygen fixation leading to irreversible DNA damage. However, under hypoxic conditions
(where O2 partial pressure (pO2) is below 10 mmHg), there is diminished production
of DNA radicals due to the low levels of oxygen and subsequently cells become more
resistant to radiotherapy [28]. Consequently, the radiation dose required to achieve the
same biological effect is about three times higher in the absence of oxygen as compared to
physiological oxygen levels [27].
3. Hypoxia in GB
Tumor hypoxia is a hallmark of GB and mainly occurs due to the abnormal neo-
vascularization observed within these tumors [29]. The blood vessels that feed the GB
are typically highly permeable and easily collapsible due to the excessive recruitment
and proliferation of endothelial cells (caused by excessive secretion of VEGFA by the
tumor cells) and lack of pericyte coverage (which are cells that provide support to the
blood vessels) [30–32]. In addition, these vessels exhibit larger diameters and possess
thicker basement membranes when compared to physiological brain blood vessels [33].
As a consequence, the occurrence of microvascular thromboses and vessel occlusions are
frequently observed in GB [34] which significantly impede blood flow leading to a het-
erogeneous microenvironment regarding tumor oxygenation [35]. Moreover, the anarchic
organization and instability of the vascular system within the tumor can lead to dynamic
phases of hypoxia and then reoxygenation within the different tumor fractions, known as
“cycling hypoxia” [36].
3.1. Regulation of HIF Transcription Factors
The cellular response to hypoxic stress is largely orchestrated by the HIF transcription
factors. HIFs are heterodimers composed of an α subunit (e.g., HIF-1α, EPAS1/HIF-2α,
or HIF-3α) which is negatively regulated by oxygen (O2) and a β subunit, HIF-1β, also
known as aryl hydrocarbon receptor nuclear translocator (ARNT), which is expressed
constitutively in cells [37,38]. Regarding protein domain structures, HIF-1α, HIF-2α, and
HIF-1β subunits all have a Per-Arnt-Sim (PAS) and a basic Helix-Loop-Helix (bHLH) do-
mains which are involved in the heterodimer assembly and binding to Hypoxia Responsive
Elements (HRE) within HIF target gene promoters and a characteristic C-Terminal Domain
(C-TAD) (Figure 1). Each HIF-α subunit also contain an Oxygen-Dependent Degradation
Domain (ODDD) that is involved in the degradation of these proteins in the presence of
normal levels of oxygen, and a specific N-Terminal Domain (N-TAD) (Figure 1). N-TAD
and C-TAD domains are able to interact with p300/CBP HIF transcriptional coactiva-
tors [39–41]. Different variants of the HIF-3α subunit containing diverse deletions of the
domains described above have been shown to exist (reviewed in [42]).
HIF transcriptional activity is highly dependent on the degradation (negative regu-
lation) or stabilization (positive regulation) of the HIF-α subunit which is regulated by
intracellular levels of oxygen. In normoxic cells, the Prolyl Hydroxylases 1-3 (PHD1-3)
hydroxylate two prolyl residues within the HIF-α subunit. This enables the binding of the
Von Hippel-Lindau (VHL) protein to the HIF-α subunit and the subsequent recruitment of
E3 ubiquitin ligases that target HIF-α for degradation via the proteasome (Figure 2) [43–45].
Hypoxia inhibits PHD activity and consequently leads to HIF-α stabilization and transloca-
tion to the nucleus where it binds to the HIF-1β subunit and p300/CBP cofactors. HIFs bind
to HRE within their target gene promoters orchestrating the hypoxic response [46–48]. The
hydroxylase, Factor-Inhibiting HIF (FIH) has also been shown to regulate HIF activity in
an oxygen dependent manner. In normoxic cells, FIH hydroxylates an asparagine residue
within the HIF-α subunit which impairs the interaction between HIF and the transcrip-
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tional activators, p300/CBP subsequently negatively impacting on HIF transcriptional
activity (Figure 2) [49,50].
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HIF-1 and HIF-2 are considered the main regulators of the hypoxia response [37,38],
while the existence of multiple variants of HIF-3α has highlighted that HIF-3 can function
in some cases as a transcriptional activator whereas certain variants can act as dominant
negative regulators of HIF-1 and/or HIF-2 transcriptional functions [42,51].
3.2. Hypoxia Independent HIF Activation in GB
Several genetic alterations leading to HIF activation, even in the absence of hypoxia,
have been reported in GB (Figure 3). These include the activation of the EGFR (either by am-
plification or mutation of the EGFR gene) and the loss of the tumor suppressor genes TP53
and Phosphatase and Tensin homolog (PTEN) [52–54]. The most common EGFR mutation
obs rved in GB is the deletion of exons 2–7 (EGFRvIII) resulting in the expression of a consti-
tutively active and ligand independent EGFRvIII receptor [55]. EGFR signaling leads to the
up-regulation of HIF-1α levels via the activation of the PI3K/AKT/mTOR pathway [56,57].
Depletion of PTEN has been reported in about 20–40% of GB [53]. PTEN constitutes the
main negative regulator of the PI3K/AKT signaling pathway. Therefore, loss of PTEN
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promotes the up-regulation of HIF-1α due to enhanced activity of the PI3K/AKT/mTOR
pathway which is observed in the absence of PTEN protein. Loss of the TP53 gene has
been linked to HIF-1α stabilization due to down-regulation of MDM2 transcription and
subsequent inhibition of MDM2 mediated ubiquitination and degradation of HIF-1α
(Figure 3) [54].
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Factor Receptor (EGFR) by EGFR gene mutation (e.g., EGFRvIII) and/or amplification frequently
occurs in GB cells resulting in activation of the PI3K/AKT/mTOR pathway with the subsequent
accumulation of HIF-1α levels. The tumor suppressor Phosphatase and Tensin homolog (PTEN)
gene is deleted in 20–40% of GBs. PTEN is the main inhibitor of the PI3K/AKT signaling pathway.
Consequently, loss of PTEN will also lead to accumulation of HIF-1α via the PI3K/AKT/mTOR
pathway. Loss of p53 inhibits MDM2-mediated ubiquitination of HIF-1α leading to its accumulation
and increased HIF activity in GB cells.
3.3. HIF Transcriptional Targets in GB
HIFs induce the transcription of hundreds of genes involved in the regulation of main
cellular processes including angiogenesis, glycolysis, autophagy, motility and invasion,
chemo- and radioresistance [58,59].
Several studies using GB cell lines and/or clinical samples support a hypoxia triggered
metabolic switch towards glycolysis including the up-regulation of HK2, PFKFB3, PFKFB4,
PFKFP, LDHA, PDK1, SLC2A1/GLUT-1, CA9/CA IX, PGAM1, ENO1, ENO2, ALDOA
and SLC16A3/ MCT-4 genes and proteins (Figure 4) [9,59,60]. Hypoxic up-regulation of
many pro-angiogenic genes and proteins is also commonly observed in GB. These include
VEGFA, VEGFC, VEGFD, PGF/PlGF, ADM and ANGPTL4 (Figure 4) [32,59,61,62]. GB is a
highly invasive tumor and hypoxia has been shown to induce proteins of the plasminogen
system. These include the plasminogen receptor, S100A10, the receptor for the urokinase
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Plasminogen Activator (uPA), uPAR and the Plasminogen Activator Inhibitor-1 (PAI-1)
(Figure 4) [59,63,64]. The co-localization of S100A10 with uPAR at the outer cell membrane
has been shown to promote the generation of the serine protease, plasmin by putting
plasminogen (inactive form of plasmin) and its activator, uPA into close proximity. This
leads to the subsequent degradation of the Extra-Cellular Matrix (ECM) by plasmin which
is a critical step in GB cell invasion. Importantly, plasmin also has the capacity to cleave
and activate many pro-MMPs, further accelerating ECM degradation [65,66]. The GB
hypoxic environment has also been shown to promote the up-regulation of autophagy
genes including BNIP-3 and DDIT4 (Figure 4) [59,67,68]. Several studies support that
during hypoxic stress autophagy allows the recycling of cellular components which is
critical for cell survival under oxygen and nutrients limiting conditions. Association
of GB hypoxia with chemoresistance has also been demonstrated. Several reports have
shown that hypoxic induction of ANGPTL4, DDIT4 and NDRG1 lead to resistance to
chemotherapy (Figure 4) [59,69–73].
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In addition, radiotherapy is more efficient in rapidly proliferating cells as compared to
slow-proliferating, quiescent and stem-like cells that are localized in the most hypoxic
regions of the tumor [28].
4.1. The Role of Cell Cycle Regulation Proteins in Hypoxia Induced Radioresistance
Several molecular mechanisms involved in cell cycle regulation have been shown to
play a role in hypoxia induced radioresistance in GB (Figures 5 and 6). A study showed
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that MEK/ERK inhibition either by treatment with the drug, U0126 or downregulation of
ERK by siRNA significantly enhanced the radiosensitivity of hypoxic T98G, U87MG and
U138MG GB cells [75]. Using a combination of siRNA approaches and chemical inhibitors
these authors further mapped the MEK/ERK/DNA-PKc/HIF-1α functional interplay in
hypoxia dependent GB radioresistance.
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Another report highlighted the role of the Fibroblast Growth Factor Receptor 1 (FGFR1)
in Phospholipase C Gamma (PlCγ)/HIF1α-dependent GB radioresistance [76]. FGFR
signalling is involved in the regulation of cell proliferation, differentiation, migration,
angiogenesis and tissue injury repair. PlCγ binds through its SH2 domain to a phos-
photyrosine residue within the C-terminal tail of FGFRs and is phosphorylated at the
tyrosine residues by the activated receptor tyrosine kinase. This phosphorylation activates
PlCγ which then hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate
inositol1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) leading to Protein Kinase C
(PKC) activation. Using in vitro and in vivo knockdown approaches, the authors were able
to demonstrate that FGFR1/PlCγ/HIF1α signalling pathway confers radioresistance to
GB cells (e.g., U87, LN18) and derived tumor mouse xenografts via controlling radiation-
induced centrosome overduplication and radiation-induced mitotic cell death.
We recently observed a significant increase in DDIT4 expression in hypoxic GB cells
(e.g., U87, SEBTA-003, SEBTA-023, UP-007, UP-029) as compared to their normoxic coun-
terpart control cells [59]. These data supported a previous report using U87 cells [67]. We
also observed high expression of DDIT4 in GB patient clinical samples, particularly in GB
hypoxic core region as compared to normal brain specimens [59]. DDIT4 gene product
is the protein, REDD1 which is involved in the activation of the Tuberous Sclerosis 1/2
(TSC1/TSC2) complex, a main negative regulator of mTORC1 [77]. Even though over-
expression of REDD1 in GB has been linked to chemo- and radioresistance the molecular
mechanisms involved in these outcomes are still not fully understood [70,78].
Phosphorylation of 4E-BP1 occurs after activation of mTORC1, which functions down-
stream of the PI3K/AKT and AMPK kinase signaling pathways [79]. As previously men-
tioned, the PI3K/AKT signaling pathway is frequently activated in GB. Consequently, this
leads to increased rates of cap-dependent translation in an mTORC1/4E-BP1–dependent
manner. Using a mouse U87 GB xenograft model, a study has shown that 4E-BP1 promotes
hypoxia dependent radioresistance [80]. These authors found that loss of 4E-BP1 expres-
sion by siRNA did not significantly affect in vitro growth of U87 GB cells, but significantly
enhanced the growth of U87 tumor xenografts. Furthermore, 4E-BP1 knockdown U87
cells were significantly more sensitive to hypoxia-induced in vitro cell death. Most impor-
tantly, 4E-BP1 knockdown cells produced tumors with reduced fractions of radioresistant
hypoxic cells.
The exosomal secretion of micro-RNA-301-a (miR-301-a) by hypoxic GB cells (e.g.,
U87, LN229, U251) has also been shown to lead to radioresistance [81]. Importantly, clinical
analysis revealed higher levels of miR-301a expression in glioma samples with high HIF-1α
levels and the percentage of serum exosomal miR-301a (low versus high) was distributed
according to the HIF-1α immunohistochemistry score. In vitro studies demonstrated that
miR-301a expression is regulated by HIF-1α. Furthermore, miR-301a directly repressed the
promoter of the tumor suppressor gene, TCEAL7 whose encoded protein binds to β-catenin
inhibiting its translocation from the cytoplasm to the nucleus. Therefore, negatively
regulating the Wnt/β-catenin signaling pathway. In summary, targeting of TCEAL7 gene
expression by miR-301a secreted by hypoxic GB cells induced enhanced activation of the
Wnt/β-catenin signaling axis leading to radioresistance.
4.2. The Role of Glycolysis in Hypoxia Induced Radioresistance
As aforementioned, hypoxia induces a metabolic reprogramming towards glycolysis
in GB cells. Interestingly, a research study has shown that modulation of the glucose
metabolism can sensitize GB cells to IR (Figures 5 and 6) [82]. Treatment of GB cells (e.g.,
U87, U251, LN229, DBTRG) with dichloroacetate, a PDK inhibitor, in combination with
radiotherapy reversed the radiotherapy-induced glycolytic shift in these cells and inhibited
their clonogenicity in vitro. Investigation into the molecular mechanism of action revealed
that dichloroacetate sensitized GB cells to radiotherapy by inducing G2–M phase cell-cycle
arrest, reducing mitochondrial reserve capacity, and increasing oxidative stress and DNA
damage in these cells [82]. In vivo studies using a mouse xenograft model showed that
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radiotherapy in combination with dichloroacetate improved the survival of orthotopic GB-
bearing mice [82]. Taking into account that hypoxia constitutes a major microenvironmental
factor that triggers glycolysis in GB (including the specific up-regulation of PDK1 [59]) this
report provides encouraging data regarding targeting the glycolytic metabolism in order to
sensitize hypoxic GB cells to radiotherapy.
4.3. The Role of ROS Regulatory Systems in Hypoxia Induced Radioresistance
Several studies have shown that the regulation of intracellular ROS levels plays a
key role in hypoxic GB radioresistance (Figures 5 and 6). ROS are radical and non-radical
oxygen-containing chemical molecules with different degrees of reactivity, including bio-
logically relevant molecules such as superoxide anion (O2−), hydroxyl radical (·OH) and
hydrogen peroxide (H2O2) [58]. Of note, H2O2 constitutes a key second messenger in many
cell signaling pathways [58,83]. However, due to their reactive properties ROS contribute
to protein oxidation, lipid peroxidation and/or DNA damage that can ultimately result
in either cell death or tumorigenesis (due to DNA mutagenesis) [58]. To overcome this
issue, cells possess several antioxidant systems that inactivate ROS and recycle oxidized
molecules (reviewed in [58]). A study showed that exposure of T98G GB cells to cycling
hypoxia induced the up-regulation of the aspartate-aminotransferase Glutamic-Oxaloacetic
Transaminase 1 (GOT1) protein, leading to increased levels of the antioxidant protein,
glutathione (GSH), decreased intracellular ROS levels and enhanced radioresistance [84].
Most importantly, targeting glutamine-dependent antioxidant capacity or glutathione
metabolism reversed the cycling hypoxia induced GB cells radioresistance. Exposure to
either acute or cycling hypoxia was shown to trigger the up-regulation of the mitochondrial
Citrate Carrier (CIC) and IDH2 in T98G GB cells in vitro [85]. CIC protein belongs to the
large family of mitochondrial metabolite carriers. It is a mitochondrial transmembrane
protein whose main function is to mediate the exchange of mitochondrial citrate for cy-
tosolic malate. This process is accompanied with the transport of one proton and therefore
can influence the mitochondrial membrane potential [86]. In fact, the tumorigenic activity
of CIC has been shown to be linked to its role in mitochondrial membrane integrity [87]
which is crucial to inhibit ROS induced apoptosis.
NADPH oxidase subunit 4 (Nox4) has been shown to mediate cycling (intermittent)
hypoxia induced radioresistance in GB cells [88]. In this report, the GBM8401 and U251
cell lines were stably transfected with a dual hypoxia HIF-1 signaling reporter construct.
The mouse tumor xenograft studies showed that Nox4 was highly expressed in the cycling
hypoxic areas within the tumor microenvironment. In addition, when compared to the
normoxic or acutely hypoxic GB cells, the cycling hypoxic GB cells derived from tumor
xenografts showed significantly higher expression of Nox4, enhanced ROS levels and
increased radioresistance which was reversed by Nox4 suppression in intracerebral GB
bearing mice [88].
Another report revealed that hypoxia increased U87 GB cell radioresistance in vitro
and in vivo via long-term induction of HIF-1 signaling transduction in a ROS dependent-
manner [89]. These authors performed clonogenic survival assays to show that hypoxia
pretreatment of U87 cells significantly increased GB cell resistance to IR compared with
normoxic U87 control cells. To determine whether HIF-1 was a crucial mediator of hypoxia-
induced radioresistance in U87 cells, they used a HIF-1 siRNA approach. Hypoxic HIF-1
knockdown U87 cells showed similar sensitivity to IR as compared to normoxic HIF-1
knockdown U87 control cells, indicating that the increased radioresistance observed in
hypoxic U87 cells was mediated by HIF-1. The authors further confirmed these results
in vivo using a mouse xenograft model [89].
4.4. The Role of Glioma Stem Cells in Radioresistance
As early as 1997, Bonnet and Dick described for the first-time leukemic cells that
could transplant leukaemia in vivo into immunodeficient mice [90]. These cells were called
“cancer stem cells” (CSCs) and were later identified in different types of cancer including
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breast, colon, lung, as well as in CNS cancers such as GB [91]. CSCs are slow-dividing small
subpopulations of tumor cells that have the ability to undergo asymmetric cell division
for self-renewal and multilineage differentiation giving rise to more mature cancer cells
that constitute the bulk of the tumor [92,93]. The CSC hypothesis states that these cells
have the ability to generate the cellular heterogeneity which is commonly observed within
tumors. CSCs, called Glioma Stem Cells (GSCs) in GB, are suspected of being a main cause
of tumor recurrence after treatment.
GSCs have been shown to have similar properties to Neural Stem Cells (NSCs). In ad-
dition to self-renewal capacity and multilineage differentiation potential, GSCs also express
stemness markers involved in the regulation of specific signaling pathways, telomerase
activity, expression of ABC transporter proteins, migration, secretion of cytokines, growth
and pro-angiogenic factors [93].
It has been shown that hypoxia treatment of GB cells (e.g., SJ-1, U87) promoted
CD133 expression (marker for GSC) and increased OCT4 and SOX2 mRNA levels, while
promoting the loss of the glial differentiation marker, GFAP [94]. These data indicate
that hypoxia promotes a GSC phenotype in GB. Another report took a broader approach
by screening cell lines of different cancer types alongside human embryonic stem cells
for overlapping changes of common genes when grown under hypoxic conditions [95].
The authors showed that OCT4, NANOG, SOX2, KLF4, cMYC, and miRNA-302 were all
induced under hypoxic conditions in 11 different cancer cell lines from prostate, brain
(U251 GB cell line), kidney, cervix, lung, colon, liver and breast tumors [95]. This report
further supported a link between hypoxia and the stem cell phenotype by showing a
correlation between the expression of HIFs and OCT4 [95].
Whether HIF-1α, HIF-2α or both transcription factors play a main role in hypoxia
induced GSC phenotype is still a theme up for debate, with many studies showing differ-
ing results [29,95–98].
It has been well established that CSCs are significantly more radioresistant as com-
pared to non-CSCs [26]. This is due to their enhanced DNA-repair capability, antioxidant
defenses (in particular ROS scavenging systems) and self-renewal potential [99]. Interest-
ingly, GSCs are found within a particular hypoxic environment, called a “niche”. This
hypoxic niche forces the GSCs to develop mechanisms of survival and resistance to this
harmful environment and also keeps the GSCs in a state of quiescence making them less
vulnerable to the effects of radiotherapy [93]. Upon radiotherapy, the GSC populations
containing advantageous genomic alterations that protect them against IR are selected and
continue to sustain the tumor leading to recurrence.
Hypoxia has been shown to promote the undifferentiated state of GSCs through the
activation of the Notch signaling pathway in a HIF dependent manner, contributing in
this manner to GB radioresistance [100]. In summary, hypoxia is able of inducing the
dedifferentiation of GB cells towards a GSCs phenotype, thus conferring aggressiveness
and increased resistance to radiotherapy.
Interestingly, Dahan et al. demonstrated that IR itself is capable of inducing ded-
ifferentiation of GB cells leading to overexpression of stem cell markers (SOX2, Nestin,
SHH, Nanog, EZH2, Olig2) and a decrease in glial and neuronal differentiation markers
(GFAP and OMgp, respectively) which resulted in increased tumorigenicity in vivo [101].
In addition, this team observed overexpression of survivin (a protein with anti-apoptotic
properties that is expressed during neurogenesis) after irradiation of GB cells. Inhibition of
this protein prevented the dedifferentiation of GB cells into GSCs [101]. This highlights a
potential signaling pathway involved in the dedifferentiation of GB cells and a prospective
therapeutic target which would make it possible to inhibit the acquisition of this stem-like
phenotype highly linked to GB recurrence.
5. Conclusions
Targeting hypoxia-mediated radioresistance is considered an attractive approach to
improve therapy outcome in GB. However, clinical trials evaluating the use of hypoxia-
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targeting agents have failed to reveal a benefit for GB patients, reviewed in [102]. This
emphasizes the need for more effective and mechanism-based therapies to overcome
hypoxia-induced radioresistance and the co-development of predictive biomarkers and
improved imaging of heterogeneous GB hypoxia to guide radiotherapy protocols. As
previously described, hypoxic areas of the tumor are more resistant to IR compared to
normoxic areas. For this reason, increased radiation doses or number of radiation cycles
within the GB hypoxic areas could be considered. Here we performed a review of the
current literature, regarding the molecular mechanisms which are activated by hypoxia
and that can potentially be targeted in the future to improve radiotherapy efficiency in GB
patients. We revealed that several signaling pathways involved in cell cycle regulation were
shown to provide radioresistance in hypoxic GB cells. These included the MEK/ERK/DNA-
PKc/HIF-1α; PI3K/AKT/mTORC1/4E-BP1; and inhibition of TCEAL7 transcription by
miR-301-a leading to activation of the Wnt/β-catenin signaling pathway. The glycolytic
metabolism which is triggered by hypoxia in GB cells was also shown to be involved in
radioresistance and its inhibition showed promising in vivo results using a mouse xenograft
model, providing radiosensitivity in the GB-bearing mice. These results are encouraging
regarding the development of glycolytic inhibiting therapy approaches in combination with
IR treatment. In addition, several ROS-dependent and Redox regulatory mechanisms were
shown to play a role in hypoxic GB radioresistance. These included enhanced expression
of GOT1 leading to increased levels of the antioxidant protein, GSH; up-regulation of
CIC which has been linked to mitochondrial membrane integrity and inhibition of ROS-
induced apoptosis; up-regulation of Nox4 and ROS-dependent up-regulation of HIF-1.
Taken together these data highlight that targeting key Redox systems in combination with
IR treatment might constitute a promising approach in GB therapy. Finally, the hypoxic
microenvironment has been shown to play a role in GSC maintenance and quiescence
which are associated with GB radioresistance. This occurs via inhibition of differentiation
markers (e.g., GFAP, OMgp) and induction of stemness markers (e.g., CD133, OCT4, SOX2,
NANOG, NESTIN, EZH2, SHH, KLF4, cMYC, Olig2).
In conclusion, targeting key cellular proteins/mechanisms involved in cell cycle regu-
lation, glycolytic metabolism, Redox regulation and/or GSC maintenance in combination
with IR treatment may potentially lead to the development of novel and effective therapies
for GB patients.
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